JP2018510206A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2018510206A5 JP2018510206A5 JP2017552093A JP2017552093A JP2018510206A5 JP 2018510206 A5 JP2018510206 A5 JP 2018510206A5 JP 2017552093 A JP2017552093 A JP 2017552093A JP 2017552093 A JP2017552093 A JP 2017552093A JP 2018510206 A5 JP2018510206 A5 JP 2018510206A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- appendix
- subject
- compound
- ester
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 150000001875 compounds Chemical class 0.000 claims description 34
- 239000008194 pharmaceutical composition Substances 0.000 claims description 31
- 102000030703 Apolipoprotein C-III Human genes 0.000 claims description 27
- 108010056301 Apolipoprotein C-III Proteins 0.000 claims description 27
- 150000002148 esters Chemical class 0.000 claims description 19
- 235000020828 fasting Nutrition 0.000 claims description 16
- 125000004435 hydrogen atoms Chemical group [H]* 0.000 claims description 15
- 150000003626 triacylglycerols Chemical class 0.000 claims description 14
- 230000001603 reducing Effects 0.000 claims description 12
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 10
- 229910052739 hydrogen Inorganic materials 0.000 claims description 10
- 239000001257 hydrogen Substances 0.000 claims description 10
- 150000003839 salts Chemical class 0.000 claims description 9
- 239000011780 sodium chloride Substances 0.000 claims description 9
- 239000000203 mixture Substances 0.000 claims description 8
- VOGXDRFFBBLZBT-AAQCHOMXSA-N 2-[(5Z,8Z,11Z,14Z,17Z)-icosa-5,8,11,14,17-pentaenoxy]butanoic acid Chemical compound CC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CCCCOC(CC)C(O)=O VOGXDRFFBBLZBT-AAQCHOMXSA-N 0.000 claims description 7
- 238000002560 therapeutic procedure Methods 0.000 claims description 7
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 claims description 6
- 125000004122 cyclic group Chemical group 0.000 claims description 6
- UFHFLCQGNIYNRP-UHFFFAOYSA-N hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 6
- 230000003078 antioxidant Effects 0.000 claims description 5
- 239000003963 antioxidant agent Substances 0.000 claims description 5
- 125000004494 ethyl ester group Chemical group 0.000 claims description 5
- -1 excipient Substances 0.000 claims description 5
- 108020004999 Messenger RNA Proteins 0.000 claims description 4
- 239000003795 chemical substances by application Substances 0.000 claims description 4
- 230000001258 dyslipidemic Effects 0.000 claims description 4
- 150000002431 hydrogen Chemical class 0.000 claims description 4
- 229920002106 messenger RNA Polymers 0.000 claims description 4
- 125000004492 methyl ester group Chemical group 0.000 claims description 4
- 102000004169 proteins and genes Human genes 0.000 claims description 4
- 108090000623 proteins and genes Proteins 0.000 claims description 4
- 125000006273 (C1-C3) alkyl group Chemical group 0.000 claims description 3
- 206010058108 Dyslipidaemia Diseases 0.000 claims description 3
- 208000009576 Hypercholesterolemia Diseases 0.000 claims description 3
- 208000006575 Hypertriglyceridemia Diseases 0.000 claims description 3
- 206010061227 Lipid metabolism disease Diseases 0.000 claims description 3
- 125000005907 alkyl ester group Chemical group 0.000 claims description 3
- 239000011230 binding agent Substances 0.000 claims description 3
- 239000003085 diluting agent Substances 0.000 claims description 3
- 201000010099 disease Diseases 0.000 claims description 3
- 239000003814 drug Substances 0.000 claims description 3
- 125000005456 glyceride group Chemical group 0.000 claims description 3
- 238000004519 manufacturing process Methods 0.000 claims description 3
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 6
- DKPFZGUDAPQIHT-UHFFFAOYSA-N Butyl acetate Chemical compound CCCCOC(C)=O DKPFZGUDAPQIHT-UHFFFAOYSA-N 0.000 description 2
- CZBZUDVBLSSABA-UHFFFAOYSA-N Butylated hydroxyanisole Chemical compound COC1=CC=C(O)C(C(C)(C)C)=C1.COC1=CC=C(O)C=C1C(C)(C)C CZBZUDVBLSSABA-UHFFFAOYSA-N 0.000 description 2
- NLZUEZXRPGMBCV-UHFFFAOYSA-N Butylhydroxytoluene Chemical compound CC1=CC(C(C)(C)C)=C(O)C(C(C)(C)C)=C1 NLZUEZXRPGMBCV-UHFFFAOYSA-N 0.000 description 2
- SBJKKFFYIZUCET-JLAZNSOCSA-N Dehydro-L-ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(=O)C1=O SBJKKFFYIZUCET-JLAZNSOCSA-N 0.000 description 2
- SKRDXYBATCVEMS-UHFFFAOYSA-N Isopropyl nitrite Chemical compound CC(C)ON=O SKRDXYBATCVEMS-UHFFFAOYSA-N 0.000 description 2
- 238000008214 LDL Cholesterol Methods 0.000 description 2
- 108010028554 LDL Cholesterol Proteins 0.000 description 2
- 229960001295 Tocopherol Drugs 0.000 description 2
- 235000019282 butylated hydroxyanisole Nutrition 0.000 description 2
- 235000010354 butylated hydroxytoluene Nutrition 0.000 description 2
- 235000020669 docosahexaenoic acid Nutrition 0.000 description 2
- 235000020673 eicosapentaenoic acid Nutrition 0.000 description 2
- 239000007903 gelatin capsule Substances 0.000 description 2
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 2
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 description 2
- 235000010384 tocopherol Nutrition 0.000 description 2
- 239000011732 tocopherol Substances 0.000 description 2
- 125000002640 tocopherol group Chemical group 0.000 description 2
- 229930003799 tocopherols Natural products 0.000 description 2
- 125000005457 triglyceride group Chemical group 0.000 description 2
- 210000002381 Plasma Anatomy 0.000 description 1
- 150000004702 methyl esters Chemical class 0.000 description 1
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2020017712A JP7341916B2 (ja) | 2015-04-01 | 2020-02-05 | アポｃ３を低下させるためのチアオキソ化合物の使用 |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PCT/IB2015/001316 WO2016156912A1 (fr) | 2015-04-01 | 2015-04-01 | Utilisation de composés thia oxo pour la réduction de l'apo c3 |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020017712A Division JP7341916B2 (ja) | 2015-04-01 | 2020-02-05 | アポｃ３を低下させるためのチアオキソ化合物の使用 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2018510206A JP2018510206A (ja) | 2018-04-12 |
| JP2018510206A5 true JP2018510206A5 (fr) | 2018-05-31 |
Family
ID=53879725
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017552093A Pending JP2018510206A (ja) | 2015-04-01 | 2015-04-01 | アポｃ３を低下させるためのチアオキソ化合物の使用 |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US20180110747A1 (fr) |
| JP (1) | JP2018510206A (fr) |
| KR (1) | KR20180010181A (fr) |
| AU (1) | AU2015389862B2 (fr) |
| MX (1) | MX2017012641A (fr) |
| RU (1) | RU2705991C2 (fr) |
| WO (1) | WO2016156912A1 (fr) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN115025079A (zh) | 2015-04-28 | 2022-09-09 | 普罗诺瓦生物医药挪威公司 | 结构增强的含硫脂肪酸在预防和/或治疗非酒精性脂肪性肝炎中的用途 |
| WO2019111048A1 (fr) | 2017-12-06 | 2019-06-13 | Basf As | Dérivés d'acide gras pour le traitement de la stéatohépatite non alcoolique |
| EP3796901A2 (fr) | 2018-05-23 | 2021-03-31 | Northsea Therapeutics B.V. | Acides gras structurellement modifiés pour améliorer la régulation glycémique et traiter une maladie intestinale inflammatoire |
| MX2023007347A (es) | 2020-12-22 | 2023-08-16 | Northsea Therapeutics B V | Terapias de combinacion que comprenden acidos grasos estructuralmente mejorados que contienen oxigeno para el tratamiento de la esteatohepatitis no alcoholica. |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2010244136B2 (en) * | 2009-05-08 | 2016-05-12 | Pronova Biopharma Norge As | Polyunsaturated fatty acids for the treatment of diseases related to cardiovascular, metabolic and inflammatory disease areas |
| JP2014505017A (ja) * | 2010-11-05 | 2014-02-27 | プロノヴァ・バイオファーマ・ノルゲ・アーエス | 脂質化合物を用いる処置方法 |
| US9492545B2 (en) * | 2012-05-07 | 2016-11-15 | Omthera Pharmaceuticals Inc. | Compositions of statins and omega-3 fatty acids |
| JP6537980B2 (ja) * | 2013-02-28 | 2019-07-03 | プロノヴァ・バイオファーマ・ノルゲ・アーエスＰｒｏｎｏｖａ ＢｉｏＰｈａｒｍａ Ｎｏｒｇｅ ＡＳ | 脂質化合物、トリグリセリドおよび界面活性剤を含む組成物、ならびにその使用方法 |
-
2015
- 2015-04-01 JP JP2017552093A patent/JP2018510206A/ja active Pending
- 2015-04-01 MX MX2017012641A patent/MX2017012641A/es unknown
- 2015-04-01 AU AU2015389862A patent/AU2015389862B2/en active Active
- 2015-04-01 KR KR1020177031665A patent/KR20180010181A/ko not_active IP Right Cessation
- 2015-04-01 WO PCT/IB2015/001316 patent/WO2016156912A1/fr active Application Filing
- 2015-04-01 US US15/562,554 patent/US20180110747A1/en not_active Abandoned
- 2015-04-01 RU RU2017137960A patent/RU2705991C2/ru active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20190732T1 (hr) | Polinezasićene masne kiseline za liječenje bolesti povezanih s kardiovaskularnim, metaboličkim i upalnim područjima bolesti | |
| JP2018515463A5 (fr) | ||
| RU2020123679A (ru) | Композиции и способы лечения и/или предотвращения сердечно-сосудистого заболевания | |
| JP2019048843A5 (fr) | ||
| JP2014505017A5 (fr) | ||
| JP2012526094A5 (fr) | ||
| JP2018510206A5 (fr) | ||
| JP2013521310A5 (fr) | ||
| JP2008540394A5 (fr) | ||
| CN110025608A (zh) | 降低心血管疾病风险的方法 | |
| JP2015143248A5 (fr) | ||
| SI2443246T1 (en) | Compounds and procedures for lowering triglycerides without increasing the levels of LDL-C in an individual who is simultaneously receiving statin therapy | |
| CN105120872B (zh) | 包含15-hepe的组合物以及其使用方法 | |
| JP2005097323A5 (fr) | ||
| RU2013121788A (ru) | Ингибиторы репликации вич | |
| JP2015503590A5 (fr) | ||
| RU2018116572A (ru) | Композиции омега-3 полиненасыщенных жирных кислот в форме свободной кислоты, обогащенные DPA | |
| JP2015520235A5 (fr) | ||
| RU2019114940A (ru) | Лечение катаплексии | |
| JP2017518334A5 (fr) | ||
| JP2010509204A5 (fr) | ||
| RU2017137960A (ru) | Применение тиаоксосоединений для уменьшения содержания аро сз | |
| JP2014505017A (ja) | 脂質化合物を用いる処置方法 | |
| EP2588103A1 (fr) | Combinaison d'atorvastatine et d'aspirine destinée à être utilisée dans le traitement de maladies cardiovasculaires | |
| JP2016501248A5 (fr) |